Related Experiment Video
Updated: Apr 17, 2026
09:30
Author Spotlight: Microbial Control and Monitoring Strategies for Cleanroom Environments and Cellular Therapies
Published on: March 17, 2023
4.8K
Pharmaceutical approval update.
P & T : a Peer-Reviewed Journal for Formulary Management
|February 13, 2015
Summary
Blinatumomab treats acute lymphoblastic leukemia, Gardasil 9 prevents HPV-related cancers, and Hysingla ER manages severe pain. These therapies offer new options for patients with these serious conditions.
Area of Science:
- Oncology
- Immunology
- Vaccinology
- Pain Management
Background:
- Acute lymphoblastic leukemia (ALL) remains a challenging hematologic malignancy.
- Cervical cancer, primarily caused by human papillomavirus (HPV), necessitates effective prevention strategies.
- Chronic severe pain requires long-term, reliable management options.
Purpose of the Study:
- To review the efficacy and safety of blinatumomab (Blincyto) for acute lymphoblastic leukemia.
- To assess the expanded indication of human papillomavirus 9-valent vaccine, recombinant (Gardasil 9) for enhanced protection against HPV-related cancers.
- To evaluate hydrocodone bitartrate extended release (Hysingla ER) for 24-hour management of severe pain.
Main Methods:
- Review of clinical trial data and regulatory submissions for blinatumomab.
- Analysis of epidemiological data and clinical studies supporting Gardasil 9's extended use.
- Examination of pharmacokinetic and pharmacodynamic studies for Hysingla ER.
Main Results:
- Blinatumomab demonstrated significant improvements in remission rates for ALL.
- Gardasil 9 showed robust immunogenicity and efficacy in preventing HPV infections and related precancers.
- Hysingla ER provided consistent 24-hour pain relief with a manageable safety profile.
Conclusions:
- Blinatumomab offers a valuable therapeutic option for patients with acute lymphoblastic leukemia.
- The expanded use of Gardasil 9 strengthens cervical cancer prevention efforts.
- Hysingla ER presents a viable long-term solution for severe pain management.
Related Concept Videos
01:26FDA Approved Drugs: Changes to Approved Drugs
336
Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...
336
01:15Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
85
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure...
85
01:25Drug Regulation
3.4K
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
3.4K
01:26Drug Administration and Therapy Phases: Overview
2.1K
Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
2.1K
01:11Clinical Trials: Overview
5.5K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
5.5K
01:28Drug Products: Biologics, Biosimilars and Interchangeables
361
Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
361